The American Psychiatric Association (APA) has updated its Privacy Policy and Terms of Use, including with new information specifically addressed to individuals in the European Economic Area. As described in the Privacy Policy and Terms of Use, this website utilizes cookies, including for the purpose of offering an optimal online experience and services tailored to your preferences.

Please read the entire Privacy Policy and Terms of Use. By closing this message, browsing this website, continuing the navigation, or otherwise continuing to use the APA's websites, you confirm that you understand and accept the terms of the Privacy Policy and Terms of Use, including the utilization of cookies.

×
No Access

The use of methylphenidate and imipramine in Gilles de la Tourette's disease in children

Published Online:https://doi.org/10.1176/ajp.134.2.195

The authors treated two children with Gilles de la Tourette's disease and one child with a probable combination of Gilles de la Tourette's disease and minimal brain dysfunction with methylphenidate, which resulted in exacerbation of symptoms. One child was briefly treated with imipramine, with similar results. The authors suggest that these pharmacologic agents should be used cautiously in treating patients with possible movement disorders (tics) and conclude that their findings lend support to the catecholamine hypothesis of the etiology of Gilles de la Tourette's disease.

Access content

To read the fulltext, please use one of the options below to sign in or purchase access.